Abatacept for SLE Arthritis (IM101-330)
Stopped Response rate in placebo group for primary outcome was 100% on interim analysis.
Conditions
- Systemic Lupus Erythematosus Arthritis
Interventions
- BIOLOGICAL: abatacept also known as Orencia also known as CTLA4-Ig
- DRUG: Placebo
Sponsor
University of California, Los Angeles
Collaborators